回复板垣等人。对“多罗比什等人。不明原发部位癌症患者的预后因素、包括微生物群在内的临床特征及治疗结果评估。2024年，，3416”的评论。
Reply to Itagaki et al. Comment on "Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. 2024, , 3416".
作者信息
Dorobisz Karolina, Dorobisz Tadeusz, Pazdro-Zastawny Katarzyna
机构信息
Department of Otolaryngology, Head and Neck Surgery, Wrocław Medical University, Borowska 213, 50-556 Wroclaw, Poland.
Department of Vascular, General and Transplantation Surgery, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.
出版信息
Cancers (Basel). 2024 Nov 26;16(23):3952. doi: 10.3390/cancers16233952.
Abstract
In his commentary [...].
摘要
在他的评论中[...]。
相似文献
1
Reply to Itagaki et al. Comment on "Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. 2024, , 3416".回复板垣等人。对“多罗比什等人。不明原发部位癌症患者的预后因素、包括微生物群在内的临床特征及治疗结果评估。2024年，，3416”的评论。
Cancers (Basel). 2024 Nov 26;16(23):3952. doi: 10.3390/cancers16233952.
2
Comment on Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. 2024, , 3416.对多罗比什等人的评论。不明原发部位癌症患者的预后因素评估、包括微生物组在内的临床特征及治疗结果。2024年，，3416。
Cancers (Basel). 2024 Nov 22;16(23):3911. doi: 10.3390/cancers16233911.
3
Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site.未知原发部位癌症患者的预后因素、包括微生物组在内的临床特征及治疗结果评估
Cancers (Basel). 2024 Oct 8;16(19):3416. doi: 10.3390/cancers16193416.
4
Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 2021, , 1176".对奥克林等人的回复。关于“霍普金斯等人。肺免疫预后指数在非小细胞肺癌患者一线阿替唑单抗联合治疗中的价值：IMPOWER150试验的亚组分析。2021年，，1176”的评论
Cancers (Basel). 2021 Jul 27;13(15):3763. doi: 10.3390/cancers13153763.
5
Reply to Mrakic-Sposta et al. Comment on "Menzel et al. Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes? 2021, , 414".对姆拉基奇 - 斯波斯塔等人的回复。关于“门泽尔等人。在研究和临床实践中用于体外测量炎症和氧化应激的常见和新型标志物——就疾病结局而言应使用哪些标志物？2021年，，414”的评论
Antioxidants (Basel). 2021 May 28;10(6):865. doi: 10.3390/antiox10060865.
6
Using Acupuncture for Adjunct Treatment for Cancer-Related Fatigue in Breast Cancer Patients Is Practicable. Reply to Hu et al. Is Acupuncture an Ideal Adjunctive Treatment for Cancer-Related Fatigue? Comment on "Choi et al. Acupuncture for Managing Cancer-Related Fatigue in Breast Cancer Patients: A Systematic Review and Meta-Analysis. 2022, , 4419".针刺辅助治疗乳腺癌患者癌因性疲乏切实可行。回复胡等人的《针刺是癌因性疲乏的理想辅助治疗方法吗？评<崔等人。针刺治疗乳腺癌患者癌因性疲乏：系统评价与Meta分析。2022年，，4419>》
Cancers (Basel). 2023 Apr 10;15(8):2227. doi: 10.3390/cancers15082227.
7
Reply to Serrano et al. Comment on "Colletti et al. Prevalence and Management of Cancer of the Rectal Stump after Total Colectomy and Rectal Sparing in Patients with Familial Polyposis: Results from a Registry-Based Study. 2022, , 298".对塞拉诺等人的回复。对“科莱蒂等人。家族性腺瘤性息肉病患者全结肠切除术后直肠残端癌的患病率及管理：基于登记研究的结果。2022年，，298”的评论
Cancers (Basel). 2022 Jul 1;14(13):3241. doi: 10.3390/cancers14133241.
8
Reply to Garnemark et al. The Swedish National Formulary for Children ePed. Comment on "Shaniv et al. A Callout for International Collaboration. Reply to Giger, E.V.; Tilen, R. Comment on "Shaniv et al. Neonatal Drug Formularies-A Global Scope. 2023, , 848". 2023, , 1803".对加内马克等人的回复。《瑞典儿童国家处方集》电子版。对“沙尼夫等人。呼吁国际合作。对吉格、E.V.；蒂伦、R.的回复。对‘沙尼夫等人。新生儿药物处方集——全球范围。2023年， ，848’的评论”的评论。2023年， ，1803” 。
Children (Basel). 2024 Oct 31;11(11):1341. doi: 10.3390/children11111341.
9
Reply to Graziosi et al. Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on "Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. 2023, , 553".对格拉齐奥西等人的回复。pT3N0M0期胃癌切除患者辅助化疗的应用原理。评“陈等人。病理淋巴结阴性T3期胃癌的预后因素及辅助化疗的作用。2023年，，553”
J Pers Med. 2023 Jun 13;13(6):988. doi: 10.3390/jpm13060988.
10
Reply to Böning et al. Comment on "Ceruti et al. Temporal Changes in the Oxyhemoglobin Dissociation Curve of Critically Ill COVID-19 Patients. 2022, , 788".回复博宁等人。对“切鲁蒂等人。危重症COVID-19患者氧合血红蛋白解离曲线的时间变化。2022年，，788”的评论
J Clin Med. 2022 Aug 4;11(15):4547. doi: 10.3390/jcm11154547.
本文引用的文献
1
Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site.未知原发部位癌症患者的预后因素、包括微生物组在内的临床特征及治疗结果评估
Cancers (Basel). 2024 Oct 8;16(19):3416. doi: 10.3390/cancers16193416.
Zotero 插件